Alzheimer’s, Dementia, and Medical Cannabis in Texas

A dementia diagnosis creates two separate questions. The first is legal: does the exact diagnosis appear in the Texas rule? The second is clinical: is there credible evidence that a specific cannabinoid product could help a specific symptom without creating greater harm? A responsible decision answers both questions and includes the person with dementia and a care partner whenever possible.

Which Dementia Diagnoses Texas Names

Texas DPS lists incurable neurodegenerative diseases as a qualifying category for permanent Texas residents.¹ DSHS states that 25 Texas Administrative Code Section 1.61 designates the diagnoses included in that category.² The rule names Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, frontotemporal lobar degeneration, Pick’s disease, corticobasal degeneration, progressive supranuclear palsy, and several other specific neurologic diseases.³

The exact diagnosis matters. A chart that says only “memory loss,” “mild cognitive impairment,” or “dementia” should not be treated as automatic eligibility. The family should ask the diagnosing clinician for the disease name and subtype, then ask the registered Texas physician to compare it with the current rule. Some causes of cognitive impairment are reversible or require a different treatment path.

What Cannabinoid Research Actually Measures

Current human research does not show that cannabis cures Alzheimer’s disease, restores lost memory, or slows the underlying neurodegeneration. Most clinical studies have examined agitation and broader neuropsychiatric symptoms, often in people with moderate or severe dementia who live in long-term care settings. That evidence cannot be generalized to prevention, early memory complaints, or disease modification.

A 2026 systematic review and meta-analysis included six randomized trials and one open-label study with 221 total participants. Randomized comparisons favored cannabinoids on several agitation and neuropsychiatric symptom scales, but the authors emphasized the small number of trials, different formulations, short follow-up, and concentrated statistical weight. The review did not find a consistent cognitive benefit. Somnolence was the clearest safety signal, occurring more often with cannabinoids.⁴

One 2022 randomized trial enrolled 60 older adults with major neurocognitive disorder and behavioral disturbance. The cannabinoid-rich oil group showed a larger reduction in agitation than placebo, but all eight discontinuations occurred in the active-treatment group. The product had a specific CBD-to-THC composition, was titrated under study conditions, and was not interchangeable with an unregulated retail product or every formulation available in Texas.⁵

Check Treatable Causes Before Adding a Cannabinoid

Agitation can be a signal of pain, infection, constipation, dehydration, hunger, medication effects, disrupted sleep, hearing or vision problems, fear, or an overwhelming environment. NIH guidance for clinicians recommends reviewing prescription and nonprescription medicines, evaluating behavioral problems, considering environmental changes, and arranging follow-up when a new medication is prescribed.⁶

Alzheimer’s care may also involve FDA-approved symptom medicines or disease-modifying treatments for selected patients. Those options have their own eligibility rules, monitoring needs, and risks. A cannabinoid should not replace an established dementia treatment, pain plan, psychiatric plan, or caregiver strategy without the clinician responsible for that care.⁷

Safety and Caregiver Questions

THC can affect memory, judgment, balance, coordination, perception, heart rate, and blood pressure. Those effects can be more consequential for a person who already has cognitive impairment, hallucinations, wandering, gait instability, swallowing problems, or difficulty reporting adverse effects. CBD can cause drowsiness, gastrointestinal symptoms, liver injury, mood changes, and drug interactions.⁸

• List every prescription, over-the-counter medicine, supplement, and cannabinoid product before the evaluation.
• Ask whether the proposed product could add to sedation from sleep medicines, antipsychotics, antidepressants, pain medicines, or antiseizure drugs.
• Record a baseline for the target symptom, alertness, walking, appetite, sleep, and falls.
• Identify who will administer each dose and prevent duplicate or accidental dosing.
• Set a review date and a stopping rule if benefit is absent or confusion, hallucinations, falls, or excessive sleepiness increase.
• Do not drive or perform hazardous tasks while impaired.

How the Texas CURT Process Works

A permanent Texas resident or care partner can use the official CURT participating physician search to identify registered clinicians.⁹ Bring the diagnostic record, medication list, care-team contacts, current symptoms, prior interventions, and the legal guardian or medical power-of-attorney documents that apply.

The registered physician decides whether the documented diagnosis qualifies and whether risk is reasonable in light of potential benefit. If approved, the physician enters the prescription in CURT. The patient or documented legal guardian then works with a licensed Texas dispensing organization. The patient does not submit a self-registration application to the state.

Prepare One Measurable Care Goal

Before the appointment, write down one symptom that causes distress or interferes with care, what has already been tried, and what meaningful improvement would look like. Track both benefit and harm. If the goal is agitation, consider frequency, duration, triggers, comfort, alertness, falls, and caregiver burden rather than relying on a general impression.

For broader context, use the Texas neurodegenerative disease guide, the dementia agitation evidence review, the medication-interaction checklist, and the complete qualifying-conditions guide.